Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Dabrafenib, trametinib, & navitoclax in BRAF mutant melanoma (Ph I & II) & other solid tumors (Ph I)

Protocol: OSU-18040

Full Title

Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only)

Melanoma Skin Cancers